Vaccines are the key technology to combat existing and emerging infectious diseases.
However, increasing the potency, quality and durability of the vaccine response remains a …

Virus-like particles (VLPs) have become key tools in biology, medicine and even
engineering. After their initial use to resolve viral structures at the atomic level, VLPs were …

The successful clinical application of immune checkpoint blockade (ICB) and chimeric
antigen receptor T cells (CAR-T) therapeutics has attracted extensive attention to …

The past decade has witnessed the accelerating development of immunotherapies for
cancer treatment. Immune checkpoint blockade therapies and chimeric antigen receptor …

Virus-like particles (VLPs) have made giant strides in the field of vaccinology over the last
three decades. VLPs constitute versatile tools in vaccine development due to their …

Virus-like particles (VLPs) have been shown to be strong activators of dendritic cells (DCs).
DCs are the most potent antigen presenting cells (APCs) and their activation prompts the …

The development of therapeutic cancer vaccines as a means to generate immune reactivity
against tumors has been explored since the early discovery of tumor-specific antigens by …

Virus-like particles (VLPs) derived from viral nucleocapsids are an important class of
nanoparticles. The structure, uniformity, stability, and function of these VLPs have attracted …

Polymers, lipids, scaffolds, microneedles, and other biomaterials are rapidly emerging as
technologies to improve the efficacy of vaccines against infectious disease and …

Introduction: Immunization has been a remarkably successful public health intervention;
however, new approaches to vaccine design are essential to counter existing and emerging …